933 F.3d 1320
Fed. Cir.2019Background
- Lilly’s ’209 patent claims an improved method of administering pemetrexed disodium with pre‑supplementation of folic acid and vitamin B12 to reduce toxicity. Claim 12 is representative.
- DRL and Hospira filed § 505(b)(2) NDAs relying on Lilly’s data but proposed to market pemetrexed as a different salt (pemetrexed ditromethamine).
- The district court construed “administration of pemetrexed disodium” to mean liquid administration of the pemetrexed disodium salt (i.e., administering the disodium salt itself after dissolution).
- The district court found literal infringement as to Hospira (because its label allowed reconstitution in saline) and found infringement under the doctrine of equivalents as to both DRL and Hospira; Lilly sought injunctions under § 271(e)(4).
- On appeal, the Federal Circuit reversed the district court’s literal‑infringement finding for Hospira (salt identity lost upon dissolution) but affirmed both judgments under the doctrine of equivalents, holding prosecution history estoppel and the disclosure‑dedication rule did not bar Lilly’s equivalents theory.
Issues
| Issue | Lilly's Argument | DRL/Hospira's Argument | Held |
|---|---|---|---|
| Literal infringement: whether administering a different pemetrexed salt dissolved in solution literally meets “administration of pemetrexed disodium” | The label/administration yields the same pemetrexed anion in solution; source‑of‑salt is not required | A different salt dissolved in saline is not the disodium salt; the claimed salt must itself be administered | Reversed as to Hospira — literal infringement requires administering the pemetrexed disodium salt itself (no literal infringement) |
| Prosecution history estoppel (tangentiality): whether Lilly’s narrowing amendment ("antifolate" → "pemetrexed disodium") surrendered equivalents like pemetrexed ditromethamine | Amendment was to avoid prior art about different antifolates; salt identity was tangential to the reason for amendment, so estoppel does not bar equivalents | Amendment narrowed the element and therefore presumptively surrendered equivalents; patentee should have claimed the specific salt if intended | Affirmed for Lilly — amendment deemed tangential to the equivalent; prosecution history estoppel does not bar equivalence here |
| Disclosure‑dedication rule: whether Akimoto’s generic disclosure dedicated pemetrexed ditromethamine to the public | The specification did not expressly disclose pemetrexed ditromethamine; Akimoto’s generic genus does not show an identifiable member | Akimoto (and ’209 references) disclose salts/generic ammonium bases and thus dedicated ditromethamine | Affirmed for Lilly — Akimoto’s generic disclosure did not sufficiently disclose/identify pemetrexed ditromethamine; no dedication |
| Merits of equivalence: whether administering ditromethamine salt is insubstantially different (function/way/result) from claimed disodium administration | Both salts deliver identical pemetrexed anion after dilution; chemical differences (cation) lack therapeutic effect and are clinically irrelevant | Chemical differences (pH, buffering, solubility) make administration substantially different | Affirmed for Lilly — district court’s factual finding that differences are insubstantial not clearly erroneous; doctrine of equivalents applies |
Key Cases Cited
- Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (1999) (limits on equivalents via prosecution history estoppel and tangentiality exception)
- Warner‑Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17 (1997) (doctrine of equivalents affirmed; equivalence assessed by function/way/result)
- Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 339 U.S. 605 (1950) (origin and policy of the doctrine of equivalents)
- Johnson & Johnston Assocs. Inc. v. R.E. Serv. Co., 285 F.3d 1046 (Fed. Cir. 2002) (disclosure‑dedication rule: unclaimed disclosed subject matter is dedicated to the public)
- SanDisk Corp. v. Kingston Tech. Co., 695 F.3d 1348 (Fed. Cir. 2012) (treatment of incorporated‑by‑reference and genus disclosures in disclosure‑dedication analysis)